Vaccinex receives Orphan Drug Designation from FDA for lead antibody product candidate
Vaccinex announced that its lead antibody product candidate, VX15, which is currently being investigated in a Phase 2 clinical trial for the treatment of Huntington’s disease (the “SIGNAL” trial), has received Orphan Drug Designation by the FDA.
August 23, 2016